胰腺癌术前与术后辅助治疗的比较

Preoperative versus postoperative adjuvant therapy for adenocarcinoma of the pancreas.

作者信息

Hoffman John P, Stitzenberg Karyn B

机构信息

Department of Surgical Oncology, Fox Chase Cancer Center, Temper University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

出版信息

Adv Surg. 2009;43:189-98. doi: 10.1016/j.yasu.2009.02.003.

DOI:10.1016/j.yasu.2009.02.003

PMID:19845178

Abstract

Because there have been no RCTs of preoperative and postoperative AT sequencing in the treatment of resectable and borderline resectable pancreatic cancer, it is impossible to assess their relative values with confidence. Three nonrandomized experiences of both treatment approaches from single institutions provide some assurance that preoperative AT is not inferior to postoperative AT. Phase II trials for both resectable and borderline resectable tumors suggest that longer median survival can be obtained by a policy of preoperative AT. We will watch the European RCT with great interest.

摘要

由于尚无关于术前和术后辅助治疗（AT）序列在可切除和交界可切除胰腺癌治疗中的随机对照试验（RCT），因此无法确切评估它们的相对价值。来自单一机构的两种治疗方法的三项非随机试验提供了一些证据，表明术前辅助治疗并不劣于术后辅助治疗。针对可切除和交界可切除肿瘤的II期试验表明，术前辅助治疗策略可使中位生存期延长。我们将密切关注欧洲的随机对照试验。